1
|
Yamaguchi H, Hayakawa S, Ma N, Shimizu H, Okawa K, Zhang Q, Yang L, Kahl D, La Cognata M, Lamia L, Abe K, Beliuskina O, Cha S, Chae K, Cherubini S, Figuera P, Ge Z, Gulino M, Hu J, Inoue A, Iwasa N, Kim A, Kim D, Kiss G, Kubono S, La Commara M, Lattuada M, Lee E, Moon J, Palmerini S, Parascandolo C, Park S, Phong V, Pierroutsakou D, Pizzone R, Rapisarda G, Romano S, Spitaleri C, Tang X, Trippella O, Tumino A, Zhang N, Lam Y, Heger A, Jacobs A, Xu S, Ma S, Ru L, Liu E, Liu T, Hamill C, Murphy ASJ, Su J, Fang X, Kwag M, Duy N, Uyen N, Kim D, Liang J, Psaltis A, Sferrazza M, Johnston Z, Li Y. RIB induced reactions: Studying astrophysical reactions with low-energy RI beam at CRIB. EPJ Web Conf 2023. [DOI: 10.1051/epjconf/202327501015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Astrophysical reactions involving radioactive isotopes (RI) often play an important role in high-temperature stellar environments. The experimental studies on the reaction rates for those are still limited mainly due to the technical difficulties in producing high-quality RI beams. A direct measurement of those reactions would be still challenging in many cases, however, we can make a reliable evaluation of the reaction rates by an indirect method or by studying the resonance prorerties. Here we ntroduce recent examples of experimental studies on such RI-involving astrophysical reactions, performed at Center for Nuclear Study, the University of Tokyo, using the low-energy RI beam separator CRIB. One is for the neutron-induced destruction reactions of 7Be in the Big-Bang nucleosynthesis, and the other is the study on the 22Mg(α, p) reaction relevant in X-ray bursts, which was performed with the resonant scattering method from the inverse reaction channel.
Collapse
|
2
|
Inoue A, Hata A, Fifer S, Hasegawa K, Ando E, Takahashi M, Ordman R, Kasahara-Kiritani M. EP10.01-003 Non-Small Cell Lung Cancer Treatment Preferences Among EGFR Mutation Patients and Physicians in Japan. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
3
|
Kogure Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Saka H, Ebi N, Inoue A, Kurata T, Fujita Y, Nishii Y, Shibayama T, Itani H, Endo T, Yamamoto N, Gemma A. 1160P Survival impact of second-line immune checkpoint inhibitors in the elderly patients with advanced squamous non-small cell lung cancer: Post-hoc analysis from a CAPITAL study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
4
|
Sato T, Sakai Y, Kawaguchi N, Inoue A. Data-driven control for multi-rate multi-input/single-output systems. ISA Trans 2022; 126:254-262. [PMID: 34417014 DOI: 10.1016/j.isatra.2021.07.035] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 07/21/2021] [Accepted: 07/21/2021] [Indexed: 06/13/2023]
Abstract
For the next generation of manufacturing, represented by Industrie 4.0, a multi-input controller is designed directly from controlled data, without using the mathematical plant model, where the ratio between the D/A conversion of multiple inputs and the A/D conversion of a single output is non-uniquely. With the proposed method, the fixed-structured controller is optimally designed by solving a model reference problem using one-shot data. Furthermore, to eliminate inter-sample ripples emerged by input oscillation, the deviation of the control inputs is also evaluated using the proposed method. As a result, a non-ripple data-driven controller is achieved. Numerical examples show that the proposed multi-rate data-driven method is superior than the conventional single-rate method.
Collapse
Affiliation(s)
- T Sato
- Department of Mechanical Engineering, Graduate School of Engineering, University of Hyogo, 2167, Shosha, Himeji, Hyogo 671-2280, Japan.
| | - Y Sakai
- Department of Mechanical Engineering, Graduate School of Engineering, University of Hyogo, 2167, Shosha, Himeji, Hyogo 671-2280, Japan.
| | - N Kawaguchi
- Department of Mechanical Engineering, Graduate School of Engineering, University of Hyogo, 2167, Shosha, Himeji, Hyogo 671-2280, Japan.
| | - A Inoue
- Okayama University, 3-1-1, Tsushima-Naka, Kitaku, Okayama-shi, 700-0082, Japan.
| |
Collapse
|
5
|
Kai Y, Mei H, Kawano H, Nakajima N, Takai A, Kumon M, Inoue A, Yamashita N. P-138 Transcriptomic signatures in trophectoderm and inner cell mass of human blastocysts with expected pregnancy rates. Hum Reprod 2022. [DOI: 10.1093/humrep/deac107.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
Is it possible to identify the molecular factors that contribute to the implantation potential of blastocysts?
Summary answer
Genes correlated with expected pregnancy rate in trophectoderm (TE) and inner cell mass (ICM) respectively were identified, and aneuploidy alone couldn’t predict the pregnancy expectation.
What is known already
The selection of suitable embryos for transfer is critical for achieving successful pregnancy outcomes in assisted reproductive technology (ART). Although pre-implantation genetic testing for aneuploidy (PGT-A) as well as morphological and chronological evaluation of embryos, have been conducted in clinical practice, they do not fully guarantee successful pregnancy. Recently, transcriptional events in early human embryonic development have been analyzed using RNA-sequencing (RNA-seq) and researchers are attempting to apply this information to ART.
Study design, size, duration
To determine the correlation between blastocyst evaluation and pregnancy rate, we retrospectively analyzed 1,890 cases underwent frozen-thawed blastocyst transfer from March 2018 to December 2020. A total of 13 blastocysts that were cryopreserved for clinical use between February 2011 and September 2018, then scheduled for disposal and with consented for research, were subjected to RNA-seq without distinguishing between conventional in vitro fertilization (c-IVF) and intracytoplasmic sperm injection (ICSI).
Participants/materials, setting, methods
Blastocysts were donated by infertile couples undergoing c-IVF or ICSI cycles at the Yamashita Shonan Yume Clinic with informed consent under ethical approval. TE and ICM cells were collected from blastocysts by using a micromanipulator and then subjected to RNA-seq. Gene expression analysis and digital karyotyping using RNA-seq were performed simultaneously for TE and ICM cells, respectively. One-way analysis of variance, chi-square test and Tukey's multiple comparison test were used for this study.
Main results and the role of chance
Blastocysts were classified into three groups to correlate with pregnancy rates based on the diameter of the blastocyst and the time to reach this size: those taking less than 130 h to reach a diameter of > 170 μm (Group 1, n = 676), those taking more than 140 h to reach a diameter of < 180 μm (Group 2, n = 158), and the rest (Group 3, n = 1,056). The pregnancy rates of Groups 1, 2 and 3 were 59.0%, 16.5%, and 34.2%, respectively (p < 0.01). Assessing the differences in overall transcripts correlated between Group 1 (n = 5), Group 2 (n = 4), and Group 3 (n = 4), 26 and 67 differentially expressed genes (DEGs) were identified in ICM and TE cells, respectively. Importantly, downregulated genes in TE of blastocysts with lower expectation of pregnancy included tight junction-related genes, such as CXADR, CLDN10, and ATP1B1, which were implicated in peri-implantation development. Digital karyotyping revealed karyotypic abnormalities and mosaicism in all groups with no common abnormalities observed, suggesting that aneuploidy alone cannot predict the pregnancy expectation.
Limitations, reasons for caution
Although 93 genes potentially related to implantation have been identified, it is still unclear how these genes are involved in implantation. In vitro implantation models using human embryos and artificial embryos currently under development are expected to contribute to the elucidation of the functions of these genes.
Wider implications of the findings
Our results provide reliable candidates for genes that could allow for non-invasive selection of high-quality blastocysts for ART and add to the knowledge base of transcriptional events in human peri-implantation development.
Trial registration number
not applicable
Collapse
Affiliation(s)
- Y Kai
- Yamashita Shonan Yume Clinic, Reproductive Medicine Research Center , Fujisawa, Japan
| | - H Mei
- RIKEN Center for Integrative Medical Sciences, Metabolic Epigenetics , Yokohama, Japan
| | - H Kawano
- Yamashita Shonan Yume Clinic, Reproductive Medicine Research Center , Fujisawa, Japan
| | - N Nakajima
- Yamashita Shonan Yume Clinic, Reproductive Medicine Research Center , Fujisawa, Japan
| | - A Takai
- Yamashita Shonan Yume Clinic, Reproductive Medicine Research Center , Fujisawa, Japan
| | - M Kumon
- RIKEN Center for Integrative Medical Sciences, Metabolic Epigenetics , Yokohama, Japan
| | - A Inoue
- RIKEN Center for Integrative Medical Sciences, Metabolic Epigenetics , Yokohama, Japan
| | - N Yamashita
- Yamashita Shonan Yume Clinic, Reproductive Medicine Research Center , Fujisawa, Japan
| |
Collapse
|
6
|
Yamaguchi H, Hayakawa S, Ma N, Shimizu H, Okawa K, Yang L, Kahl D, La Cognata M, Lamia L, Abe K, Beliuskina O, Cha S, Chae K, Cherubini S, Figuera P, Ge Z, Gulino M, Hu J, Inoue A, Iwasa N, Kim A, Kim D, Kiss G, Kubono S, La Commara M, Lattuada M, Lee E, Moon J, Palmerini S, Parascandolo C, Park S, Phong VH, Pierroutsakou D, Pizzone R, Rapisarda G, Romano S, Spitaleri C, Tang X, Trippella O, Tumino A, Zhang N, Lam Y, Heger A, Jacobs A, Xu S, Ma S, Ru L, Liu E, Liu T, Hamill C, St J. Murphy A, Su J, Fang X, Kwag M, Duy N, Uyen N, Kim D, Liang J, Psaltis A, Sferrazza M, Johnston Z, Li Y. Experimental studies on astrophysical reactions at the low-energy RI beam separator CRIB. EPJ Web Conf 2022. [DOI: 10.1051/epjconf/202226003003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Experimental studies on astrophysical reactions involving radioactive isotopes (RI) often accompany technical challenges. Studies on such nuclear reactions have been conducted at the low-energy RI beam separator CRIB, operated by Center for Nuclear Study, the University of Tokyo. We discuss two cases of astrophysical reaction studies at CRIB; one is for the 7Be+n reactions which may affect the primordial 7Li abundance in the Big-Bang nucleosynthesis, and the other is for the 22Mg(α, p) reaction relevantin X-raybursts.
Collapse
|
7
|
Nakagawa T, Fukuhara T, Imai K, Igusa R, Yokota H, Watanabe K, Suzuki A, Morita M, Inoue A, Miura M, Minamiya Y, Maemondo M. FP05.05 A Prospective Observational Study of Osimertinib Using Plasma Concentrations in NSCLC With Acquired EGFR T790M Mutation. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Saito G, Kogure Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Saka H, Ebi N, Inoue A, Kurata T, Yamanaka T, Ando M, Shibayama T, Itani H, Nishii Y, Fujita Y, Yamamoto N, Gemma A. 1333P Dose and schedule modifications of carboplatin plus nab-paclitaxel for elderly patients with squamous non-small cell lung cancer from the CAPITAL study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
9
|
Hiramoto S, Taniyama T, Kikuchi A, Hori T, Yoshioka A, Inoue A. 1520P Effect of molecular targeting agents and immune-checkpoint inhibitors use near the end of life patients with advanced cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
10
|
Hayashi T, Umegaki H, Makino T, Huang CH, Inoue A, Shimada H, Kuzuya M. Combined Impact of Physical Frailty and Social Isolation on Rate of Falls in Older Adults. J Nutr Health Aging 2020; 24:312-318. [PMID: 32115613 DOI: 10.1007/s12603-020-1316-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
OBJECTIVES The aim of this study was to examine the impact of the combination of physical frailty and social isolation on falling in community-dwelling older adults. DESIGN A cross-sectional study of data obtained at registration in a randomized control trial. SETTING Community-based study of participants recruited from Toyota, Japan. PARTICIPANTS 380 community-dwelling older adults (47.9% women, mean age = 72.3 ± 4.6 years). MEASUREMENTS Participants were categorized as non-frail or pre-frail/frail based on the Fried frailty criteria (slowness, weakness, exhaustion, low activity, and weight loss). Social isolation was examined using the Lubben Social Network Scale (LSNS-6), and scores lower than 12 points indicated social isolation. Participants were divided into four groups depending on pre-frail/frail status and social isolation, and experiences of multiple falls over the past year were compared between the groups. RESULTS Participants were classified into robust (n = 193), physical frailty (PF; n = 108), social isolation (SI; n = 43), and PF with SI (PF+SI; n = 36) groups. A total of 38 (10.0%) participants reported multiple falls. Logistic regression analysis showed that PF and SI groups were not independently associated with falling (PF: OR 1.64, 95% CI 0.65-4.16, SI: OR 2.25, 95% CI 0.77-6.58), while PF+SI group was significantly associated with falling compared with the robust group (OR 3.06, 95% CI 1.00-9.34, p = 0.049) after controlling for confounding factors. CONCLUSION Our findings support the assertion that coexistence with physical frailty and social isolation were associated with falling in the older adults.
Collapse
Affiliation(s)
- T Hayashi
- Hiroyuki Umegaki, Department of Community Healthcare and Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan, Tel: +81-52-741-2364, Fax: +81-52-744-2371,
| | | | | | | | | | | | | |
Collapse
|
11
|
Baba K, Tanaka H, Fujita Y, Nakamura A, Kikuchi E, Kawai Y, Harada T, Watanabe N, Yokouchi H, Usui K, Saito R, Watanabe H, Masuda T, Fukuhara T, Kudo K, Honda R, Oizimi S, Maemondo M, Inoue A, Morikawa N. A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Tanaka H, Miyauchi E, Nakamura A, Harada T, Nakagawa T, Morita M, Jingu D, Tomoya K, Gamou S, Saito R, Inoue A. EP1.01-04 Phase I/II Trial of Biweekly Nab-Paclitaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer: NJLCG1402. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Iwata H, Iimuro S, Inoue A, Miyauchi K, Taguchi I, Hiro T, Nakagawa Y, Ozaki Y, Ohashi Y, Daida H, Shimokawa H, Kimura T, Nagai R. P5320Reduction in high-sensitivity C-reactive protein by pitavastatin was associated with improved outcomes in Japanese patients with stable coronary artery disease: results from REAL-CAD study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The effect of statins on lowering high sensitivity C-reactive protein (hs-CRP) as well as low density lipoprotein cholesterol (LDL-C) has been associated with reduced risk for cardiovascular events in patients with elevated hs-CRP. However, it remains unclear whether this statin effect applies to low-risk patients with stable coronary artery disease (CAD). In this pre-specified sub-study within the REAL-CAD trial, we explored the association between achieved LDL-C/hs-CRP levels and cardiovascular events in Japanese patients with stable CAD who were treated with pitavastatin 1 mg or 4 mg/day.
Methods
The REAL-CAD trial randomly allocated 13,054 patients with stable CAD to pitavastatin 1 mg or 4 mg/day. LDL-C and hs-CRP were measured at baseline and at 6 months after randomization. We excluded those patients without 6-month data and those with endpoint events before 6 months (N=1915). The primary endpoint of the study was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization. Outcomes were assessed by landmark analysis beyond 6 months among 4 groups that were configured based on LDL-C (median) and hs-CRP (median) targets: achieving neither target, achieving LDL-C target only, achieving hs-CRP target only, and achieving both targets. Data were adjusted for baseline characteristics including age, gender, diabetes and baseline values of LDL-C and hs-CRP.
Results
Median LDL-C and hs-CRP levels were 88 mg/dL and 0.52 mg/L at baseline and 80 mg/dL and 0.48 mg/L after 6 months, respectively. There was no correlation between the change in LDL-C and hs-CRP levels from baseline to 6 months (correlation coefficient: 0.009, P=0.331). Of the 11,677 patients included in the study, 25.1% (N=2799) achieved both LDL-C and hs-CRP targets, 25.3% (N=2282) met neither target, 24.8% (N=2765) met only the hs-CRP target, and 24.7% (N=2753) met only the LDL-C target. Risk of primary endpoint occurrence was significantly lower in those achieving either or both targets than in those meeting neither target (Figure A). In the subgroup analysis stratified by the randomized dose of pitavastatin, the risk for the primary endpoint was significantly lower in patients achieving both targets in both the 1mg and 4 mg arms, and in patients achieving only hs-CRP target in the 1 mg arm (Figure B, C).
Figure 1
Conclusions
In this subanalysis of the REAL-CAD trial, the hs-CRP lowering effect of pitavastatin was independent from LDL-C lowering. Lower achieved hs-CRP was associated with lower risk for cardiovascular events in Japanese patients with stable CAD.
Acknowledgement/Funding
Public Health Research Foundation, The company manufacturing the study drug (Kowa Pharmaceutical Co Ltd) was one of the entities providing financial s
Collapse
Affiliation(s)
- H Iwata
- Juntendo University School of Medicine, Tokyo, Japan
| | - S Iimuro
- Teikyo University, Teikyo Academic Research Center, Tokyo, Japan
| | - A Inoue
- Dokkyo Medical University, Mibu, Japan
| | - K Miyauchi
- Juntendo University School of Medicine, Tokyo, Japan
| | - I Taguchi
- Dokkyo Medical University Koshigya Hospital, Koshigaya City, Japan
| | - T Hiro
- Nihon University, Tokyo, Japan
| | - Y Nakagawa
- Shiga University of Medical Science, Otsu, Japan
| | - Y Ozaki
- Fujita Health University School of Medicine, Toyoake, Japan
| | - Y Ohashi
- Chuo University, Department of Integrated Science and Technology for Sustainable Society, Tokyo, Japan
| | - H Daida
- Juntendo University School of Medicine, Tokyo, Japan
| | - H Shimokawa
- Tohoku University Graduate School of Medicine, Sendai, Japan
| | - T Kimura
- Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - R Nagai
- Jichi Medical University, Shimotsuke, Japan
| |
Collapse
|
14
|
Harada T, Udagawa H, Sugiyama E, Atagi S, Koyama R, Watanabe S, Nakamura Y, Harada D, Hataji O, Tanaka F, Niimi A, Kida H, Satouchi M, Inoue A, Urata Y, Yamane Y, Yoh K, Yoshioka H, Yamanaka T, Goto K. P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.589] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
15
|
Seike M, Inoue A, Sugawara S, Morita S, Hosomi Y, Ikeda S, Watanabe K, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Kobayashi K, Nukiwa T. Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Tran DT, Ong HJ, Hagen G, Morris TD, Aoi N, Suzuki T, Kanada-En'yo Y, Geng LS, Terashima S, Tanihata I, Nguyen TT, Ayyad Y, Chan PY, Fukuda M, Geissel H, Harakeh MN, Hashimoto T, Hoang TH, Ideguchi E, Inoue A, Jansen GR, Kanungo R, Kawabata T, Khiem LH, Lin WP, Matsuta K, Mihara M, Momota S, Nagae D, Nguyen ND, Nishimura D, Otsuka T, Ozawa A, Ren PP, Sakaguchi H, Scheidenberger C, Tanaka J, Takechi M, Wada R, Yamamoto T. Evidence for prevalent Z = 6 magic number in neutron-rich carbon isotopes. Nat Commun 2018; 9:1594. [PMID: 29686394 PMCID: PMC5913314 DOI: 10.1038/s41467-018-04024-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2018] [Accepted: 03/28/2018] [Indexed: 11/08/2022] Open
Abstract
The nuclear shell structure, which originates in the nearly independent motion of nucleons in an average potential, provides an important guide for our understanding of nuclear structure and the underlying nuclear forces. Its most remarkable fingerprint is the existence of the so-called magic numbers of protons and neutrons associated with extra stability. Although the introduction of a phenomenological spin-orbit (SO) coupling force in 1949 helped in explaining the magic numbers, its origins are still open questions. Here, we present experimental evidence for the smallest SO-originated magic number (subshell closure) at the proton number six in 13-20C obtained from systematic analysis of point-proton distribution radii, electromagnetic transition rates and atomic masses of light nuclei. Performing ab initio calculations on 14,15C, we show that the observed proton distribution radii and subshell closure can be explained by the state-of-the-art nuclear theory with chiral nucleon-nucleon and three-nucleon forces, which are rooted in the quantum chromodynamics.
Collapse
Affiliation(s)
- D T Tran
- Research Center for Nuclear Physics, Osaka University, Osaka, 567-0047, Japan
- Institute of Physics, Vietnam Academy of Science and Technology, Hanoi, 10000, Vietnam
| | - H J Ong
- Research Center for Nuclear Physics, Osaka University, Osaka, 567-0047, Japan.
| | - G Hagen
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA
- Department of Physics and Astronomy, University of Tennessee, Knoxville, TN, 37996, USA
| | - T D Morris
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA
- Department of Physics and Astronomy, University of Tennessee, Knoxville, TN, 37996, USA
| | - N Aoi
- Research Center for Nuclear Physics, Osaka University, Osaka, 567-0047, Japan
| | - T Suzuki
- Department of Physics, College of Humanities and Sciences, Nihon University, Tokyo, 156-8550, Japan
- National Astronomical Observatory of Japan, Tokyo, 181-8588, Japan
| | - Y Kanada-En'yo
- Department of Physics, Kyoto University, Kyoto, 606-8502, Japan
| | - L S Geng
- School of Physics and Nuclear Energy Engineering, Beihang University, 100191, Beijing, China
| | - S Terashima
- School of Physics and Nuclear Energy Engineering, Beihang University, 100191, Beijing, China
| | - I Tanihata
- Research Center for Nuclear Physics, Osaka University, Osaka, 567-0047, Japan
- School of Physics and Nuclear Energy Engineering, Beihang University, 100191, Beijing, China
| | - T T Nguyen
- Pham Ngoc Thach University of Medicine, Ho Chi Minh, 700000, Vietnam
- Faculty of Physics and Engineering, VNUHCM-University of Science, Ho Chi Minh City, 70250, Vietnam
- Sungkyunkwan University, Gyeonggi-do, 16419, South Korea
| | - Y Ayyad
- Research Center for Nuclear Physics, Osaka University, Osaka, 567-0047, Japan
| | - P Y Chan
- Research Center for Nuclear Physics, Osaka University, Osaka, 567-0047, Japan
| | - M Fukuda
- Department of Physics, Osaka University, Osaka, 560-0043, Japan
| | - H Geissel
- GSI Helmholtzzentrum für Schwerionenforschung, 64291, Darmstadt, Germany
- Justus Liebig University, 35392, Giessen, Germany
| | - M N Harakeh
- GSI Helmholtzzentrum für Schwerionenforschung, 64291, Darmstadt, Germany
- KVI Center for Advanced Radiation Technology, University of Groningen, 9747 AA, Groningen, The Netherlands
| | - T Hashimoto
- Rare Isotope Science Project, Institute for Basic Science, Daejeon, 34047, Korea
| | - T H Hoang
- Research Center for Nuclear Physics, Osaka University, Osaka, 567-0047, Japan
- Institute of Physics, Vietnam Academy of Science and Technology, Hanoi, 10000, Vietnam
| | - E Ideguchi
- Research Center for Nuclear Physics, Osaka University, Osaka, 567-0047, Japan
| | - A Inoue
- Research Center for Nuclear Physics, Osaka University, Osaka, 567-0047, Japan
| | - G R Jansen
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA
- National Center for Computational Sciences, Oak Ridge National Laboratory, Oak Ridge, TN, 37831, USA
| | - R Kanungo
- Astronomy and Physics Department, Saint Mary's University, Halifax, NS, B3H 3C3, Canada
| | - T Kawabata
- Department of Physics, Kyoto University, Kyoto, 606-8502, Japan
| | - L H Khiem
- Institute of Physics, Vietnam Academy of Science and Technology, Hanoi, 10000, Vietnam
| | - W P Lin
- Institute of Modern Physics, Chinese Academy of Sciences, 730000, Lanzhou, China
| | - K Matsuta
- Department of Physics, Osaka University, Osaka, 560-0043, Japan
| | - M Mihara
- Department of Physics, Osaka University, Osaka, 560-0043, Japan
| | - S Momota
- Kochi University of Technology, Kochi, 782-8502, Japan
| | - D Nagae
- RIKEN Nishina Center, Saitama, 351-0198, Japan
| | - N D Nguyen
- Dong Nai University, Dong Nai, 81000, Vietnam
| | - D Nishimura
- Tokyo University of Science, Chiba, 278-8510, Japan
| | - T Otsuka
- Department of Physics, University of Tokyo, Tokyo, 113-0033, Japan
| | - A Ozawa
- Institute of Physics, University of Tsukuba, Ibaraki, 305-8571, Japan
| | - P P Ren
- Institute of Modern Physics, Chinese Academy of Sciences, 730000, Lanzhou, China
| | - H Sakaguchi
- Research Center for Nuclear Physics, Osaka University, Osaka, 567-0047, Japan
| | - C Scheidenberger
- GSI Helmholtzzentrum für Schwerionenforschung, 64291, Darmstadt, Germany
- Justus Liebig University, 35392, Giessen, Germany
| | - J Tanaka
- Research Center for Nuclear Physics, Osaka University, Osaka, 567-0047, Japan
| | - M Takechi
- Department of Physics, Niigata University, Niigata, 950-2181, Japan
| | - R Wada
- Institute of Modern Physics, Chinese Academy of Sciences, 730000, Lanzhou, China
- Cyclotron Institute, Texas A&M University, College Station, TX, 77840, USA
| | - T Yamamoto
- Research Center for Nuclear Physics, Osaka University, Osaka, 567-0047, Japan
| |
Collapse
|
17
|
Tsutsumi A, Kajiki S, Muto T, Shimazu A, Okahara S, Ohdo K, Yoshikawa T, Mishiba T, Inoue A. 1152 Collecting and organising basic occupational health data for international comparisons. Epidemiology 2018. [DOI: 10.1136/oemed-2018-icohabstracts.380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
18
|
Kawakami N, Imamura K, Asai Y, Watanabe K, Tsutsumi A, Shimazu A, Inoue A, Hiro H, Odagiri Y, Yoshikawa T, Yoshikawa E. 1211 The stress check program: an evaluation of the first-year implementation of the new national workplace mental health program in japan. Health Serv Res 2018. [DOI: 10.1136/oemed-2018-icohabstracts.444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
19
|
Inoue A, Tamii A, Abe K, Adachi S, Aoi N, Asai M, Fukuda M, Gey G, Hashimoto T, Ideguchi E, Isaak J, Kobayashi N, Maeda Y, Makii H, Matsuta K, Mihara M, Miura M, Shima T, Shimizu H, Tang R, Dinh Trong T, Yamaguchi H, Yang L. Study of the contribution of the 7Be( d, p) reaction to the 7Li problem in the Big-Bang Nucleosynthesis. EPJ Web Conf 2018. [DOI: 10.1051/epjconf/201818402007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Our research goal is to measure the 7Be(d, p) reaction to shed light on the 7Li problem in the Big-Bang Nucleosynthesis. We are developing an unstable 7Be target for a high-resolution measurement of the 7Be(d, p)8Be reaction. We plan to compare two methods to producethe 7Be target: (1) Activation method, and (2) Implantation method. We performed an activation methodexperiment at the Van de Graaff at Osaka University, and obtained the cross-section data. A second experiment to obtain more accurate data will take place at the Tandem Electrostatic Accelerator, Kobe University. We have also made a 7Be target with implantation method at CRIB, Center for Nuclear Study, Univer-sity of Tokyo. An experiment to measure the (d, p) reaction with the implanted target is scheduled for 2018 at Japan Atomic Energy Agency, tandem facility.
Collapse
|
20
|
Ebe H, Matsumoto I, Kawaguchi H, Kurata I, Tanaka Y, Inoue A, Kondo Y, Tsuboi H, Sumida T. Clinical and functional significance of STEAP4-splice variant in CD14 + monocytes in patients with rheumatoid arthritis. Clin Exp Immunol 2017; 191:338-348. [PMID: 29080328 DOI: 10.1111/cei.13076] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/24/2017] [Indexed: 01/25/2023] Open
Abstract
Tumour necrosis factor alpha (TNF)-α-induced adipose-related protein (TIARP) is a negative regulator of inflammation in arthritis model mice. In humans, six-transmembrane epithelial antigen of prostate 4 (STEAP4) (human counterpart of TIARP) is also expressed in CD14+ monocytes from patients with rheumatoid arthritis (RA). Recently, highly levels of exon 3-spliced variant STEAP4 (v-STEAP4) expression have been observed in porcine lung. The aim of this study is to elucidate the expression and functional role of v-STEAP4, comparing it with that of STEAP4, in the pathogenesis of arthritis. We identified v-STEAP4 in CD14+ cells. The expression of STEAP4 and v-STEAP4 was higher in patients with RA than in healthy participants. We also found that STEAP4 and v-STEAP4 were correlated positively with C-reactive protein and that their expression was decreased after treatment with an interleukin (IL)-6 antagonist in patients with RA. To investigate further the role of STEAP4 and v-STEAP4, we produced STEAP4 and v-STEAP4 over-expressing human monocytic cell lines (THP-1) for functional analysis. In the v-STEAP4 over-expressing cells, the production of IL-6 was suppressed significantly, but TNF-α was increased significantly through lipopolysaccharide (LPS) stimulation. Immunoblot analysis revealed that phosphorylated (p-)nuclear factor kappa B (NF-κB) was increased after LPS stimulation and degradation of nuclear factor kappa B inhibitor alpha (IκBα) was sustained, whereas p-signal transducer and activator of transcription 3 (STAT-3) was decreased with v-STEAP4. We identified specific up-regulation of v-STEAP4 in RA monocytes. V-STEAP4 might play a crucial role in the production of TNF-α and IL-6 through NF-κB and STAT-3 pathways, resulting in the generation of RA.
Collapse
Affiliation(s)
- H Ebe
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - I Matsumoto
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - H Kawaguchi
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - I Kurata
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - Y Tanaka
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - A Inoue
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - Y Kondo
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - H Tsuboi
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - T Sumida
- Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| |
Collapse
|
21
|
Fukuhara T, Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Watanabe S, Ito K, Gemma A, Demura Y, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T. P2.03-010 Updated Survival Outcomes of NEJ005/TCOG0902, a Randomized PII of Gefitinib and Chemotherapy in EGFR-Mutant NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Nishio M, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, Hida T, Yoshioka H, Harada M, Ohe Y, Nogami N, Murakami H, Takeuchi K, Inamura S, Kuriki H, Shimada T, Tamura T. OA 05.08 Final Result of Phase I/II Study (AF-001JP) of Alectinib, a Selective CNS-Active ALK Inhibitor, in ALK+ NSCLC Patients (Pts). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
23
|
Kato H, Fukuda Y, Hasegawa A, Seki M, Fukiya K, Taguchi T, Inoue A, Utsumi H, Terashi H, Aizawa H. The neuropsychological evaluation including word fluency test in the patients with cerebral white matter ischemia. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Kato K, Komiyama S, Takeshima N, Takano H, Inoue A, Hongo A, Asai-Sato M, Arakawa A, Kubushiro K, Kamiura S, Sugiyama T. Prospective cohort study of bevacizumab plus standard platinum based chemotherapy as front-line treatment for advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: Japanese Gynecologic Oncology Group study (JGOG3022). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Han FF, Inoue A, Han Y, Kong FL, Zhu SL, Shalaan E, Al-Marzouki F, Greer AL. Novel Heating-Induced Reversion during Crystallization of Al-based Glassy Alloys. Sci Rep 2017; 7:46113. [PMID: 28406157 PMCID: PMC5390259 DOI: 10.1038/srep46113] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Accepted: 03/08/2017] [Indexed: 11/17/2022] Open
Abstract
Thermal stability and crystallization of three multicomponent glassy alloys, Al86Y7Ni5Co1Fe0.5Pd0.5, Al85Y8Ni5Co1Fe0.5Pd0.5 and Al84Y9Ni4Co1.5Fe0.5Pd1, were examined to assess the ability to form the mixture of amorphous (am) and fcc-aluminum (α-Al) phases. On heating, the glass transition into the supercooled liquid is shown by the 85Al and 84Al glasses. The crystallization sequences are [am] → [am + α-Al] → [α-Al + compounds] for the 86Al and 85Al alloys, and [am] → [am + α-Al + cubic AlxMy (M = Y, Ni, Co, Fe, Pd)] → [am + α-Al] → [α-Al + Al3Y + Al9(Co, Ni)2 + unknown phase] for the 84Al alloy. The glass transition appears even for the 85Al alloy where the primary phase is α-Al. The heating-induced reversion from [am + α-Al + multicomponent AlxMy] to [am + α-Al] for the 84Al alloy is abnormal, not previously observed in crystallization of glassy alloys, and seems to originate from instability of the metastable AlxMy compound, in which significant inhomogeneous strain is caused by the mixture of solute elements. This novel reversion phenomenon is encouraging for obtaining the [am + α-Al] mixture over a wide range of high temperature effective for the formation of Al-based high-strength nanostructured bulk alloys by warm working.
Collapse
Affiliation(s)
- F F Han
- School of Materials Science and Engineering, Tianjin University, Tianjin, 300072, China
| | - A Inoue
- School of Materials Science and Engineering, Tianjin University, Tianjin, 300072, China.,International Institute of Green Materials, Josai International University, Togane, 283-8555, Japan.,Department of Physics, King Abdulaziz University, Jeddah, 22254, Saudi Arabia.,MISiS, National University of Science and Technology, Moscow, 119049, Russia
| | - Y Han
- School of Materials Science and Engineering, Tianjin University, Tianjin, 300072, China
| | - F L Kong
- International Institute of Green Materials, Josai International University, Togane, 283-8555, Japan
| | - S L Zhu
- School of Materials Science and Engineering, Tianjin University, Tianjin, 300072, China
| | - E Shalaan
- Department of Physics, King Abdulaziz University, Jeddah, 22254, Saudi Arabia
| | - F Al-Marzouki
- Department of Physics, King Abdulaziz University, Jeddah, 22254, Saudi Arabia
| | - A L Greer
- Department of Materials Science and Metallurgy, University of Cambridge, Cambridge CB3 0FS, UK
| |
Collapse
|
26
|
Maemondo M, Fukuhara T, Sugawara S, Takiguchi Y, Inoue A, Oizumi S, Ishii Y, Yoshizawa H, Isobe T, Gemma A, Morita S, Hagiwara K, Kobayashi K, Nukiwa T. NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.86] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
27
|
Kogure Y, Saka H, Takiguchi Y, Atagi S, Kurata T, Ebi N, Inoue A, Kubota K, Takenoyama M, Seto T, Kada A, Yamanaka T, Ando M, Yamamoto N, Gemma A, Ichinose Y. Carboplatin (Cb) plus nab-paclitaxel (PTX) versus docetaxel (D) for elderly squamous (Sq) non-small cell lung cancer (NSCLC) (CAPITAL study). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.99] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Inoue A, Yamane Y, Koga T. Abstract PR105. Anesth Analg 2016. [DOI: 10.1213/01.ane.0000492511.20588.55] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
29
|
Inoue A, Nakajima T, Nakajima A, Uemoto Y, Fukushima M, Yoshida E, Iwamoto E, Akiyama T, Kohama N, Kobayashi E, Oyama K, Honda T, Mannen H, Sasazaki S. P1005 Genome-wide association study identifies a QTL for fat percentage in ribeye area on BTA10 in Japanese Black cattle. J Anim Sci 2016. [DOI: 10.2527/jas2016.94supplement417x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Nagura Y, Tsuno NH, Kano K, Inoue A, Aoki J, Hirowatari Y, Kaneko M, Kurano M, Matsuhashi M, Ohkawa R, Tozuka M, Yatomi Y, Okazaki H. Regulation of the lysophosphatidylserine and sphingosine 1-phosphate levels in autologous whole blood by the pre-storage leukocyte reduction. Transfus Med 2016; 26:365-372. [DOI: 10.1111/tme.12326] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2016] [Revised: 05/14/2016] [Accepted: 05/24/2016] [Indexed: 11/28/2022]
Affiliation(s)
- Y. Nagura
- Department of Transfusion Medicine; The University of Tokyo Hospital; Tokyo Japan
- Analytical Laboratory Chemistry, Graduate School of Health Care Sciences; Tokyo Medical and Dental University; Tokyo Japan
| | - N. H. Tsuno
- Department of Transfusion Medicine; The University of Tokyo Hospital; Tokyo Japan
| | - K. Kano
- Graduate School of Pharmaceutical Sciences; Tohoku University; Miyagi Japan
| | - A. Inoue
- Graduate School of Pharmaceutical Sciences; Tohoku University; Miyagi Japan
| | - J. Aoki
- Graduate School of Pharmaceutical Sciences; Tohoku University; Miyagi Japan
| | - Y. Hirowatari
- Laboratory Sciences, Department of Health Sciences; Saitama Prefectural University; Saitama Japan
| | - M. Kaneko
- Department of Clinical Laboratory; The University of Tokyo Hospital; Tokyo Japan
| | - M. Kurano
- Department of Clinical Laboratory; The University of Tokyo Hospital; Tokyo Japan
| | - M. Matsuhashi
- Department of Transfusion Medicine; The University of Tokyo Hospital; Tokyo Japan
- Laboratory Sciences, Department of Health Sciences; Saitama Prefectural University; Saitama Japan
| | - R. Ohkawa
- Analytical Laboratory Chemistry, Graduate School of Health Care Sciences; Tokyo Medical and Dental University; Tokyo Japan
| | - M. Tozuka
- Analytical Laboratory Chemistry, Graduate School of Health Care Sciences; Tokyo Medical and Dental University; Tokyo Japan
| | - Y. Yatomi
- Department of Clinical Laboratory; The University of Tokyo Hospital; Tokyo Japan
| | - H. Okazaki
- Department of Transfusion Medicine; The University of Tokyo Hospital; Tokyo Japan
| |
Collapse
|
31
|
Tran D, Nguyen T, Tanihata I, Ong H, Fukuda M, Aoi N, Ayyad Y, Sakaguchi H, Tanaka J, Chan P, Hoang T, Hashimoto T, Ideguchi E, Inoue A, Kawabata T, Khiem L, Matsuta K, Mihara M, Momota S, Nagae D, Ozawa A, Ren P, Terashima S, Wada R, Lin W, Yamamoto T. Charge-changing cross section measurement of neutron-rich carbon isotopes at 50 AMeV. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611707023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Miki R, Kikuta S, Koga T, Kai S, Inoue A, Kawase T, Ishihara S, Nakayama S. Incidence of venous thromboembolism in japanese trauma population. Intensive Care Med Exp 2015. [PMCID: PMC4796885 DOI: 10.1186/2197-425x-3-s1-a378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
O'Hayre M, Inoue A, Kufareva I, Wang Z, Mikelis CM, Drummond RA, Avino S, Finkel K, Kalim KW, DiPasquale G, Guo F, Aoki J, Zheng Y, Lionakis MS, Molinolo AA, Gutkind JS. Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells. Oncogene 2015; 35:3771-80. [PMID: 26616858 PMCID: PMC4885800 DOI: 10.1038/onc.2015.442] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Revised: 09/15/2015] [Accepted: 10/15/2015] [Indexed: 01/06/2023]
Abstract
G proteins and their cognate G protein-coupled receptors (GPCRs) function as critical signal transduction molecules that regulate cell survival, proliferation, motility and differentiation. The aberrant expression and/or function of these molecules have been linked to the growth, progression and metastasis of various cancers. As such, the analysis of mutations in the genes encoding GPCRs, G proteins and their downstream targets provides important clues regarding how these signaling cascades contribute to malignancy. Recent genome-wide sequencing efforts have unveiled the presence of frequent mutations in GNA13, the gene encoding the G protein Gα13, in Burkitt's lymphoma and diffuse large B-cell lymphoma (DLBCL). We found that mutations in the downstream target of Gα13, RhoA, are also present in Burkitt's lymphoma and DLBCL. By multiple complementary approaches, we now show that that these cancer-specific GNA13 and RHOA mutations are inhibitory in nature, and that the expression of wild-type Gα13 in B-cell lymphoma cells with mutant GNA13 has limited impact in vitro but results in a remarkable growth inhibition in vivo. Thus, although Gα13 and RhoA activity has previously been linked to cellular transformation and metastatic potential of epithelial cancers, our findings support a tumor suppressive role for Gα13 and RhoA in Burkitt's lymphoma and DLBCL.
Collapse
Affiliation(s)
- M O'Hayre
- Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
| | - A Inoue
- Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan.,PRESTO, Japan Science and Technology Agency (JST), Kawaguchi, Saitama, Japan
| | - I Kufareva
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA
| | - Z Wang
- Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
| | - C M Mikelis
- Department of Biomedical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA
| | - R A Drummond
- Fungal Pathogenesis Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - S Avino
- Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.,Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende (Cs), Italy
| | - K Finkel
- Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
| | - K W Kalim
- Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - G DiPasquale
- Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
| | - F Guo
- Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - J Aoki
- Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan.,Japan Agency for Medical Research and Development, Core Research for Evolutional Science and Technology (AMED-CREST), AMED, Chiyoda-ku, Tokyo, Japan
| | - Y Zheng
- Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - M S Lionakis
- Fungal Pathogenesis Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - A A Molinolo
- Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA
| | - J S Gutkind
- Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.,Department of Pharmacology, UC San Diego Moores Cancer Center, La Jolla, CA, USA
| |
Collapse
|
34
|
Takeuchi K, Togashi Y, Kamihara Y, Fukuyama T, Yoshioka H, Inoue A, Katsuki H, Kiura K, Nakagawa K, Seto T, Maemondo M, Hida T, Harada M, Ohe Y, Nogami N, Yamamoto N, Nishio M, Tamura T. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol 2015; 27:185-92. [PMID: 26487585 PMCID: PMC4684157 DOI: 10.1093/annonc/mdv501] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2015] [Accepted: 10/08/2015] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Anaplastic lymphoma kinase (ALK) fusions need to be accurately and efficiently detected for ALK inhibitor therapy. Fluorescence in situ hybridization (FISH) remains the reference test. Although increasing data are supporting that ALK immunohistochemistry (IHC) is highly concordant with FISH, IHC screening needed to be clinically and prospectively validated. PATIENTS AND METHODS In the AF-001JP trial for alectinib, 436 patients were screened for ALK fusions through IHC (n = 384) confirmed with FISH (n = 181), multiplex RT-PCR (n = 68), or both (n = 16). IHC results were scored with iScore. RESULT ALK fusion was positive in 137 patients and negative in 250 patients. Since the presence of cancer cells in the samples for RT-PCR was not confirmed, ALK fusion negativity could not be ascertained in 49 patients. IHC interpreted with iScore showed a 99.4% (173/174) concordance with FISH. All 41 patients who had iScore 3 and were enrolled in phase II showed at least 30% tumor reduction with 92.7% overall response rate. Two IHC-positive patients with an atypical FISH pattern responded to ALK inhibitor therapy. The reduction rate was not correlated with IHC staining intensity. CONCLUSIONS Our study showed (i) that when sufficiently sensitive and appropriately interpreted, IHC can be a stand-alone diagnostic for ALK inhibitor therapies; (ii) that when atypical FISH patterns are accompanied by IHC positivity, the patients should be considered as candidates for ALK inhibitor therapies, and (iii) that the expression level of ALK fusion is not related to the level of response to ALK inhibitors and is thus not required for patient selection. REGISTRATION NUMBER JapicCTI-101264 (This study is registered with the Japan Pharmaceutical Information Center).
Collapse
Affiliation(s)
- K Takeuchi
- Pathology Project for Molecular Targets Division of Pathology, the Cancer Institute, Japanese Foundation for Cancer Research, Tokyo
| | - Y Togashi
- Pathology Project for Molecular Targets Division of Pathology, the Cancer Institute, Japanese Foundation for Cancer Research, Tokyo
| | | | | | | | - A Inoue
- Tohoku University Hospital, Miyagi
| | - H Katsuki
- Chugai Pharmaceutical Co. Ltd, Tokyo
| | - K Kiura
- Okayama University Hospital, Okayama
| | - K Nakagawa
- Kinki University Hospital Faculty of Medicine, Osaka
| | - T Seto
- National Kyushu Cancer Center, Fukuoka
| | | | - T Hida
- Aichi Cancer Center, Aichi
| | - M Harada
- National Hospital Organization Hokkaido Cancer Center, Hokkaido
| | - Y Ohe
- National Cancer Center Hospital, Tokyo
| | | | | | - M Nishio
- The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - T Tamura
- St Luke's International Hospital, Tokyo, Japan
| |
Collapse
|
35
|
Guy AT, Nagatsuka Y, Ooashi N, Inoue M, Nakata A, Greimel P, Inoue A, Nabetani T, Murayama A, Ohta K, Ito Y, Aoki J, Hirabayashi Y, Kamiguchi H. Glycerophospholipid regulation of modality-specific sensory axon guidance in the spinal cord. Science 2015; 349:974-7. [DOI: 10.1126/science.aab3516] [Citation(s) in RCA: 72] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
36
|
Takai C, Matsumoto I, Inoue A, Umeda N, Tanaka Y, Kurashima Y, Wada Y, Narita I, Sumida T. Specific overexpression of tumour necrosis factor-α-induced protein (TNFAIP)9 in CD14(+) CD16(-) monocytes in patients with rheumatoid arthritis: comparative analysis with TNFAIP3. Clin Exp Immunol 2015; 180:458-66. [PMID: 25683200 DOI: 10.1111/cei.12606] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Revised: 02/02/2015] [Accepted: 02/09/2015] [Indexed: 01/09/2023] Open
Abstract
The tumour necrosis factor (TNF)-α-induced proteins (TNFAIP)9 and TNFAIP3 play an important pathogenic role in murine arthritis. To clarify their pathophysiological roles in patients with rheumatoid arthritis (RA), we examined their expression and localization in peripheral blood mononuclear cells (PBMC). TNFAIP9 and TNFAIP3 mRNA expression was determined in PBMC of RA patients and healthy subjects (control). Flow cytometry was used to analyse the main TNFAIP9- and TNFAIP3-expressing cell populations. TNFAIP9 and TNFAIP3 mRNA expression levels were examined in vitro on CD14(+) cells stimulated with TNF-α and lipopolysaccharide (LPS). The expression levels of TNFAIP9 and TNFAIP3 mRNA were also measured before and 12 weeks after treatment with tocilizumab and abatacept. TNFAIP9 expression was significantly higher, while TNFAIP3 expression was lower in PBMC of RA (n=36) than the control (n=24) (each P < 0.05). TNFAIP9 was expressed on CD14(+) cells, especially in human leucocyte antigen D-related (HLA-DR)(+) CD14(bright) CD16(-) cells, while TNFAIP3 was expressed mainly on CD3(+) T cells. TNF-α and LPS induced TNFAIP9 and TNFAIP3 in human CD14(+) monocytes in vitro. Treatment with tocilizumab (n=13), but not abatacept (n=11), significantly reduced TNFAIP9 mRNA expression in PBMC, which was associated with reduction in the number of circulating CD14(bright) monocytes. The expression of TNFAIP9 in CD14(+) cells was specifically elevated in patients with RA, regulated by TNF-α and LPS, and suppressed by tocilizumab, while TNFAIP3 in PBMC showed different localization and induction patterns.
Collapse
Affiliation(s)
- C Takai
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba.,Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medicine and Dental Sciences, Niigata, Japan
| | - I Matsumoto
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba
| | - A Inoue
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba
| | - N Umeda
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba
| | - Y Tanaka
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba
| | - Y Kurashima
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba
| | - Y Wada
- Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medicine and Dental Sciences, Niigata, Japan
| | - I Narita
- Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medicine and Dental Sciences, Niigata, Japan
| | - T Sumida
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba
| |
Collapse
|
37
|
Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Ann Oncol 2015; 26:888-894. [DOI: 10.1093/annonc/mdv063] [Citation(s) in RCA: 87] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2014] [Accepted: 02/02/2015] [Indexed: 12/13/2022] Open
|
38
|
Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, Nakamura Y, Ohmatsu H, Sugawara S, Minato K, Fukuda M, Yokoyama A, Takeuchi M, Michimae H, Gemma A, Kudoh S. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol 2015; 26:1401-8. [PMID: 25908605 PMCID: PMC4478975 DOI: 10.1093/annonc/mdv190] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2014] [Accepted: 04/13/2015] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Platinum-based two-drug combination chemotherapy has been standard of care for patients with advanced nonsmall-cell lung cancer (NSCLC). The primary aim was to compare overall survival (OS) of patients with advanced NSCLC between the two chemotherapy regimens. Secondary end points included progression-free survival (PFS), response, safety, and quality of life (QoL). PATIENTS AND METHODS Patients with previously untreated stage IIIB or IV NSCLC, an Eastern Cooperative Oncology Group performance status of 0-1 and adequate organ function were randomized to receive either oral S-1 80 mg/m(2)/day on days 1-21 plus cisplatin 60 mg/m(2) on day 8 every 4-5 weeks, or docetaxel 60 mg/m(2) on day 1 plus cisplatin 80 mg/m(2) on day 1 every 3-4 weeks, both up to six cycles. RESULTS A total of 608 patients from 66 sites in Japan were randomized to S-1 plus cisplatin (n = 303) or docetaxel plus cisplatin (n = 305). OS for oral S-1 plus cisplatin was noninferior to docetaxel plus cisplatin [median survival, 16.1 versus 17.1 months, respectively; hazard ratio = 1.013; 96.4% confidence interval (CI) 0.837-1.227]. Significantly higher febrile neutropenia (7.4% versus 1.0%), grade 3/4 neutropenia (73.4% versus 22.9%), grade 3/4 infection (14.5% versus 5.3%), and grade 1/2 alopecia (59.3% versus 12.3%) were observed in the docetaxel plus cisplatin than in the S-1 plus cisplatin. There were no differences found in PFS or response between the two arms. QoL data investigated by EORTC QLQ-C30 and LC-13 favored the S-1 plus cisplatin. CONCLUSION Oral S-1 plus cisplatin is not inferior to docetaxel plus cisplatin and is better tolerated in Japanese patients with advanced NSCLC. CLINICAL TRIAL NUMBER UMIN000000608.
Collapse
Affiliation(s)
- K Kubota
- Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo
| | - H Sakai
- Department of Thoracic Oncology, Saitama Cancer Center, Kita-adachi-gun
| | - N Katakami
- Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe
| | - M Nishio
- Department of Thoracic Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo
| | - A Inoue
- Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai
| | - H Okamoto
- Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Hodogaya-ku
| | - H Isobe
- Department of Medical Oncology, KKR Sapporo Medical Center, Sapporo
| | - H Kunitoh
- Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo
| | - Y Takiguchi
- Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba
| | - K Kobayashi
- Department of Respiratory Medicine, Saitama Medical University International Medical Center, Saitama
| | - Y Nakamura
- Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki
| | - H Ohmatsu
- Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa
| | - S Sugawara
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai
| | - K Minato
- Department of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota
| | - M Fukuda
- Department of Respiratory Medicine, National Hospital Organization Nagasaki Medical Center, Omura
| | - A Yokoyama
- Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata
| | - M Takeuchi
- Department of Clinical Medicine (Biostatistics and Pharmaceutical Medicine), Kitasato University School of Pharmacy, Tokyo
| | - H Michimae
- Department of Clinical Medicine (Biostatistics and Pharmaceutical Medicine), Kitasato University School of Pharmacy, Tokyo
| | - A Gemma
- Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo
| | - S Kudoh
- Double-Barred Cross Hospital Japan Anti-Tuberculosis Association, Tokyo, Japan
| | | |
Collapse
|
39
|
Miyauchi E, Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer--data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Jpn J Clin Oncol 2015; 45:670-6. [DOI: 10.1093/jjco/hyv054] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Accepted: 03/24/2015] [Indexed: 11/13/2022] Open
|
40
|
Tamura T, Seto T, Nakagawa K, Maemondo M, Inoue A, Hida T, Yoshioka H, Harada M, Ohe Y, Nogami N, Murakami H, Takeuchi K, Asakawa T, Kikuchi K, Tanaka T, Nishio M. Updated Data of a Phase 1/2 Study (AF-001JP) of Alectinib, a CNS-Penetrant, Highly Selective ALK Inhibitor in ALK-rearranged Advanced NSCLC. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.08.031] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
41
|
Uwamizu A, Inoue A, Suzuki K, Okudaira M, Shuto A, Shinjo Y, Ishiguro J, Makide K, Ikubo M, Nakamura S, Jung S, Sayama M, Otani Y, Ohwada T, Aoki J. Lysophosphatidylserine analogues differentially activate three LysoPS receptors. J Biochem 2014; 157:151-60. [DOI: 10.1093/jb/mvu060] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
|
42
|
Tanaka Y, Matsumoto I, Inoue A, Umeda N, Takai C, Sumida T. Antigen-specific over-expression of human cartilage glycoprotein 39 on CD4+ CD25+ forkhead box protein 3+ regulatory T cells in the generation of glucose-6-phosphate isomerase-induced arthritis. Clin Exp Immunol 2014; 177:419-27. [PMID: 24730590 DOI: 10.1111/cei.12349] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/26/2014] [Indexed: 01/09/2023] Open
Abstract
Human cartilage gp-39 (HC gp-39) is a well-known autoantigen in rheumatoid arthritis (RA). However, the exact localization, fluctuation and function of HC gp-39 in RA are unknown. Therefore, using a glucose-6-phosphate isomerase (GPI)-induced model of arthritis, we investigated these aspects of HC gp-39 in arthritis. The rise in serum HC gp-39 levels was detected on the early phase of GPI-induced arthritis (day 7) and the HC gp-39 mRNA was increased significantly on splenic CD4(+) T cells on day7, but not on CD11b(+) cells. Moreover, to identify the characterization of HC gp-39(+) CD4(+) T cells, we assessed the analysis of T helper (Th) subsets. As a result, HC gp-39 was expressed dominantly in CD4(+) CD25(+) forkhead box protein 3 (FoxP3)(+) refulatory T cells (T(reg)), but not in Th1, Th2 or Th17 cells. Furthermore, to investigate the effect of HC gp-39 to CD4(+) T cells, T cell proliferation assay and cytokine production from CD4(+) T cells using recombinant HC gp-39 was assessed. We found that GPI-specific T cell proliferation and interferon (IFN)-γ or interleukin (IL)-17 production were clearly suppressed by addition of recombinant HC gp-39. Antigen-specific over-expression of HC gp-39 in splenic CD4(+) CD25(+) FoxP3(+) T(reg) cells occurs in the induction phase of GPI-induced arthritis, and addition of recombinant HC gp-39 suppresses antigen-specific T-cell proliferation and cytokine production, suggesting that HC gp-39 in CD4(+) T cells might play a regulatory role in arthritis.
Collapse
Affiliation(s)
- Y Tanaka
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | | | | | | | | | | |
Collapse
|
43
|
Tsukita Y, Morikawa N, Sugawara S, Maemondo M, Harada T, Harada M, Inoue A, Kawashima Y, Fujita Y, Kato T, Yokouchi H, Watanabe H, Usui K, Suzuki T, Oizumi S, Nagai H, Kanbe M, Nukiwa T. Final Results of a Randomized Phase 2 Study Comparing Carboplatin Plus Irinotecan (Ci) Versus Carboplatin Plus Amrubicin (Ca) for Extensive Disease Small-Cell Lung Cancer: Njlcg0901. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu355.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
44
|
Inoue A, Mafune K, Nakagawa Y, Tsutsumi Y, Hino A, Miyazaki Y, Yanagida K, Tanaka N, Hori C, Masuda K, Hiro H. P-33 * JOB STRAIN, SOCIAL SUPPORT AT WORK, AND SMOKING RELAPSE AMONG JAPANESE MALE EMPLOYEES: A THREE-YEAR PROSPECTIVE COHORT STUDY. Alcohol Alcohol 2014. [DOI: 10.1093/alcalc/agu054.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Ishimoto O, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T. Randomized Phase Ii Study of Concurrent Versus Sequential Alternating Gefitinib and Chemotherapy in Previously Untreated Non-Small Cell Lung Cancer (Nsclc) with Sensitive Egfr Mutations: Nej005/Tcog0902. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.63] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Maemondo M, Inoue A, Sugawara S, Mori Y, Oizumi S, Harada M, Taima K, Morikawa N, Ishida T, Kinoshita I, Watanabe H, Suzuki T, Nakagawa T, Saito R, Nukiwa T. Final Result of Randomized Phase 2 Trial Comparing Amrubicin (A) with Re-Challenge of Platinum Doublet (P) in Patients (Pts) with Sensitive-Relapsed Small-Cell Lung Cancer (Sclc): Njlcg0702. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu355.9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Abstract
Abstract
The structure of a new amorphous Al87Y8Ni5, indicating high strength and good ductility, was studied by anomalous X-ray scattering (AXS). For comparison, a binary amorphous Al90Y10 alloy was also investigated. The environmental radial distribution functions around Y and Ni as well as the ordinary RDF in the ternary alloy, and the environmental RDF around Y and the ordinary RDF in the binary alloy were determined. From the analysis of these RDFs it is found that the Y atoms are completely surrounded by Al in the binary alloy, and that some of these Al atoms are replaced by Ni atoms in the ternary alloy.
Collapse
Affiliation(s)
- E. Matsubara
- Research Institute of Mineral Dressing and Metallurgy (SENKEN), Sendai 980, Japan
| | - Y. Waseda
- Research Institute of Mineral Dressing and Metallurgy (SENKEN), Sendai 980, Japan
| | - A. Inoue
- Institute of Materials Research, Sendai 980, Japan
| | - Ohtera
- Institute of Materials Research, Sendai 980, Japan
| | - T. Masumoto
- Institute of Materials Research, Sendai 980, Japan
| |
Collapse
|
48
|
Kannan V, Misra BK, Kapadia A, Bajpai R, Deshpande S, Almel S, Sankhe M, Desai K, Shaikh M, Anand V, Kannan A, Teo WY, Ross J, Bollo R, Seow WT, Tan AM, Kang SG, Kim DS, Li XN, Lau CC, Mohila CA, Adesina A, Su J, Ichimura K, Fukushima S, Matsushita Y, Tomiyama A, Niwa T, Suzuki T, Nakazato Y, Mukasa A, Kumabe T, Nagane M, Iuchi T, Mizoguchi M, Tamura K, Sugiyama K, Nakada M, Kanemura Y, Yokogami K, Matsutani M, Shibata T, Nishikawa R, Takami H, Fukushima S, Fukuoka K, Yanagisawa T, Nakamura T, Arita H, Narita Y, Shibui S, Nishikawa R, Ichimura K, Matsutani M, Sands S, Guerry W, Kretschmar C, Donahue B, Allen J, Matsutani M, Nishikawa R, Kumabe T, Sugiyama K, Nakamura H, Sawamura Y, Fujimaki T, Hattori E, Arakawa Y, Kawabata Y, Aoki T, Miyamoto S, Kagawa N, Hirayama R, Fujimoto Y, Chiba Y, Kinoshita M, Takano K, Eino D, Fukuya S, Nakanishi K, Yamamoto F, Hashii Y, Hashimoto N, Hara J, Yoshimine T, Murray M, Bartels U, Nishikawa R, Fangusaro J, Matsutani M, Nicholson J, Sumerauer D, Zapotocky M, Churackova M, Cyprova S, Zamecnik J, Malinova B, Kyncl M, Tichy M, Stary J, Lassen-Ramshad Y, von Oettingen G, Agerbaek M, Ohnishi T, Kohno S, Inoue A, Ohue S, Kohno S, Iwata S, Inoue A, Ohue S, Kumon Y, Ohnishi T, Acharya S, DeWees T, Shinohara E, Perkins S, Kato H, Fuji H, Nakasu Y, Ishida Y, Okawada S, Yang Q, Guo C, Chen Z, Alapetite C, Faure-Conter C, Verite C, Pagnier A, Laithier V, Entz-Werle N, Gorde-Grosjean S, Palenzuela G, Lemoine P, Frappaz D, Nguyen HA, Bui L, Ngoc, Cerbone M, Ederies A, Losa L, Moreno C, Sun K, Spoudeas HA, Nakano Y, Okada K, Kosaka Y, Nagashima T, Hashii Y, Kagawa N, Soejima T, Osugi Y, Sakamoto H, Hara J, Nicholson J, Alapetite C, Kortmann RD, Garre ML, Ricardi U, Saran F, Frappaz D, Calaminus G, Muda Z, Menon B, Ibrahim H, Rahman EJA, Muhamad M, Othman IS, Thevarajah A, Cheng S, Kilday JP, Laperriere N, Drake J, Bouffet E, Bartels U, Sakamoto H, Matsusaka Y, Watanabe Y, Umaba R, Hara J, Osugi Y, Alapetite C, Ruffier-Loubiere A, De Marzi L, Bolle S, Claude L, Habrand JL, Brisse H, Frappaz D, Doz F, Bourdeaut F, Dendale R, Mazal A, Fournier-Bidoz N, Fujimaki T, Fukuoka K, Shirahata M, Suzuki T, Adachi JI, Mishima K, Wakiya K, Matsutani M, Nishikawa R, Fukushima S, Yamashita S, Kato M, Nakamura H, Takami H, Suzuki T, Yanagisawa T, Mukasa A, Kumabe T, Nagane M, Sugiyama K, Tamura K, Narita Y, Shibui S, Shibata T, Ushijima T, Matsutani M, Nishikawa R, Ichimura K, Consortium IGA, Calaminus G, Kortmann RD, Frappaz D, Alapetite C, Garre ML, Ricardi U, Saran FH, Nicholson J, Calaminus G, Kortmann RD, Frappaz D, Alapetite C, Garre ML, Ricardi U, Saran FH, Nicholson J, Czech T, Nicholson J, Frappaz D, Kortmann RD, Alapetite C, Garre ML, Ricardi U, Saran F, Calaminus G, Hayden J, Bartels U, Calaminus G, Joseph R, Nicholson J, Hale J, Lindsay H, Kogiso M, Qi L, Yee TW, Huang Y, Mao H, Lin F, Baxter P, Su J, Terashima K, Perlaky L, Lau C, Parsons D, Chintagumpala M, Li XAN, Osorio D, Vaughn D, Gardner S, Mrugala M, Ferreira M, Keene C, Gonzalez-Cuyar L, Hebb A, Rockhill J, Wang L, Yamaguchi S, Burstein M, Terashima K, Ng HK, Nakamura H, He Z, Suzuki T, Nishikawa R, Natsume A, Terasaka S, Dauser R, Whitehead W, Adesina A, Sun J, Munzy D, Gibbs R, Leal S, Wheeler D, Lau C, Dhall G, Robison N, Judkins A, Krieger M, Gilles F, Park J, Lee SU, Kim T, Choi Y, Park HJ, Shin SH, Kim JY, Robison N, Dhir N, Khamani J, Margol A, Wong K, Britt B, Evans A, Nelson M, Grimm J, Finlay J, Dhall G. GERM CELL TUMOURS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Umeda N, Matsumoto I, Inoue A, Tanaka Y, Takai C, Kurashima Y, Kondo Y, Tsuboi H, Ogishima H, Suzuki T, Sumida T. AB0136 Clinical Aspects and Pathogenicity of Anti-Cyclic Citrullinated Glucose-6-Phospate Isomerase Peptide (CCG) Antibodies in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
50
|
Harada N, Hiramatsu N, Oze T, Morishita N, Yamada R, Hikita H, Miyazaki M, Yakushijin T, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Oshita M, Mita E, Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Inoue A, Hayashi N, Takehara T. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin. J Viral Hepat 2014; 21:357-65. [PMID: 24716638 DOI: 10.1111/jvh.12151] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Accepted: 06/20/2013] [Indexed: 12/09/2022]
Abstract
Pegylated interferon (Peg-IFN) plus ribavirin combination therapy is effective in patients with hepatitis C virus (HCV) infection and normal alanine aminotransferase levels (NALT). However, it remains unclear whether the risk of hepatocellular carcinoma (HCC) incidence is actually reduced in virological responders. In this study, HCC incidence was examined for 809 patients with NALT (ALT ≤ 40 IU/mL) treated with Peg-IFN alpha-2b and ribavirin for a mean observation period of 36.2 ± 16.5 months. The risk factors for HCC incidence were analysed by Kaplan-Meier method and Cox proportional hazards model. On multivariate analysis among NALT patients, the risk of HCC incidence was significantly reduced in patients with sustained virological response (SVR) or relapse compared with those showing nonresponse (NR) (SVR vs NR, hazard ratio (HR): 0.16, P = 0.009, relapse vs NR, HR: 0.11, P = 0.037). Other risk factors were older age (≥65 years vs <60 years, HR: 6.0, P = 0.032, 60-64 vs <60 years, HR: 3.2, P = 0.212) and male gender (HR: 3.9, P = 0.031). Among 176 patients with PNALT (ALT ≤ 30 IU/mL), only one patient developed HCC and no significant risk factors associated with HCC development were found. In conclusion, antiviral therapy for NALT patients with HCV infection can lower the HCC incidence in responders, particularly for aged and male patients. The indication of antiviral therapy for PNALT (ALT ≤ 30 IU/mL) patients should be carefully determined.
Collapse
Affiliation(s)
- N Harada
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|